HNSBF (Hansa Biopharma AB) Cyclically Adjusted Book per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNSBF Hansa Biopharma AB HNSBF
56 GF Score
Price $2.90
GF Value $2.22
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Cyclically Adjusted Book per Share?

Hansa Biopharma AB HNSBF 56 Cyclically Adjusted Book per Share is $0.00 as of Mar. 2026. GuruFocus rates HNSBF with a GF Score™ of 56/100 and a GF Value™ of $2.22 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Hansa Biopharma AB's adjusted book value per share for the three months ended in Mar. 2026 was $0.000. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Hansa Biopharma AB's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Hansa Biopharma AB was 3.70% per year. The lowest was -5.60% per year. And the median was -0.95% per year.

As of today (2026-07-14), Hansa Biopharma AB's current stock price is $2.90. Hansa Biopharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.00. Hansa Biopharma AB's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Hansa Biopharma AB was 16.92. The lowest was 1.50. And the median was 3.31.


Hansa Biopharma AB  (OTCPK:HNSBF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Hansa Biopharma AB was 16.92. The lowest was 1.50. And the median was 3.31.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Hansa Biopharma AB Cyclically Adjusted Book per Share Related Terms


Hansa Biopharma AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Cyclically Adjusted Book per Share Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.30 1.36 1.21 0.97 0.97

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.39 0.89 0.97 0.00

HNSBF vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Cyclically Adjusted PB Ratio falls into.


HNSBF
56GF Score
Hansa Biopharma AB HNSBF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hansa Biopharma AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/133.5600*133.5600
=0.000

Current CPI (Mar. 2026) = 133.5600.

Hansa Biopharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.595 101.019 0.787
201609 0.502 101.138 0.663
201612 0.879 102.022 1.151
201703 0.768 102.022 1.005
201706 0.653 102.752 0.849
201709 0.591 103.279 0.764
201712 1.988 103.793 2.558
201803 1.896 103.962 2.436
201806 1.620 104.875 2.063
201809 1.485 105.679 1.877
201812 2.383 105.912 3.005
201903 2.245 105.886 2.832
201906 2.006 106.742 2.510
201909 1.719 107.214 2.141
201912 1.491 107.766 1.848
202003 1.203 106.563 1.508
202006 1.015 107.498 1.261
202009 3.398 107.635 4.216
202012 3.340 108.296 4.119
202103 3.026 108.360 3.730
202106 2.762 108.928 3.387
202109 2.340 110.338 2.832
202112 1.874 112.486 2.225
202203 1.495 114.825 1.739
202206 1.077 118.384 1.215
202209 0.709 122.296 0.774
202212 1.108 126.365 1.171
202303 0.755 127.042 0.794
202306 0.323 129.407 0.333
202309 -0.107 130.224 -0.110
202312 -0.311 131.912 -0.315
202403 -0.682 132.205 -0.689
202406 -0.318 132.716 -0.320
202409 -0.477 132.304 -0.482
202412 -0.818 132.987 -0.822
202503 -0.938 132.825 -0.943
202506 -0.560 133.699 -0.559
202509 -0.723 133.480 -0.723
202512 -0.096 133.390 -0.096
202603 0.000 133.560 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.00 mean?
Hansa Biopharma AB (HNSBF) has a Cyclically Adjusted Book per Share of $0.00 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Cyclically Adjusted Book per Share too high?
Hansa Biopharma AB's current Cyclically Adjusted Book per Share is $0.00. Overall, Hansa Biopharma AB has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Hansa Biopharma AB's Cyclically Adjusted Book per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Cyclically Adjusted Book per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (HNSBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.22, compared to a current price of $2.90 — trading 30.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is $0.00. Hansa Biopharma AB's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Hansa Biopharma AB (HNSBF), the current Cyclically Adjusted Book per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (HNSBF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of $2.90 is trading 30.6% above its estimated GF Value™ of $2.22. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for HNSBF:

  • Cyclically Adjusted Book per Share: $0.00
  • GF Value™: $2.22 vs. price of $2.90 (30.6% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the HNSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
56GF Score

Get the complete analysis for HNSBF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90
Price
$2.22
GF Value